Sanofi S. A. (SNY)

[Tordal]

 

Gleichzeitig wird die Guidance für 2022 angehoben.:

Zitat

Sanofi said it now expects full year 2022 business EPS to grow ~15%at CER, barring unforeseen major adverse events. Applying average July 2022 exchange rates, the positive currency impact on 2022 business EPS is estimated between +7.5% to +8.5%.

 

[Tordal]

Sanofi stürzt in zwei Tagen um 15 Euro ab. Von 95 auf nun 80 €.

 

Grund könnte dieser sein:

 

Quelle: Seeking Alpha

 

Sollte es weiter deutlich runtergehen (ca. 75 €), kaufe ich nach. hier steht ja sogar, dass es short-term-impact ist. Sanofi sehe ich weiterhin sehr gut aufgestellt und deutlich unterbewertet. 

[Tordal]

Sanofi stock rises as Dupixent shows benefit in lung disease smokers, meets phase 3 goals

 

Zitat

 

The French pharma giant said Dupixent (dupilumab) showed the potential to become the first biologic to treat COPD by showing significant reduction in exacerbations in trial.

The late stage study, dubbed BOREAS, enrolled 939 adults, who were current or former smokers aged 40 to 80 years with moderate-to-severe COPD and evidence of type 2 inflammation. The patients received Dupixent (n=468) or placebo (n=471), added to maximal standard-of-care inhaled therapy (triple therapy). BOREAS is one of two trials in the Dupixent COPD program.

Patients on Dupixent experienced, 30% reduction in moderate or severe acute COPD exacerbations over 52 weeks, which was the main goal of the trial.

Sanofi said Dupixent is the first and only biologic to demonstrate clinically meaningful and statistically significant reduction in exacerbations compared to placebo.

In addition, the company said Dupixent is the first and only biologic to show rapid and significant improvement in lung function.

Patients receiving Dupixent showed improved lung function from baseline by 160 mL at 12 weeks compared to 77 mL for placebo, with the benefit compared to placebo sustained through week 52, both of which were key secondary goals of the study according to the company.

Dupixent also showed improvements in quality of life and respiratory symptoms of COPD, according to the company.

"We took a bold approach with our direct to Phase 3 program, shaving years off standard clinical development timelines. We are excited to share these unprecedented and potentially paradigm-shifting clinical results, which may give new hope to patients, caregivers and physicians," said Dietmar Berger, head of Global R&D ad interim and chief medical officer at Sanofi.

The company said safety was generally consistent with the known safety profile of Dupixent. Overall rates of adverse events (AEs) were 77% for Dupixent and 76% for placebo.

The companies plan to share the results with results with regulatory authorities.

COPD is a respiratory disease which damages the lungs and causes progressive lung function decline. Smoking is a key risk factor for COPD, but even people who quit smoking can still develop the disease, according to the company.

 

SA

[Mol_LE]

Dividenden Ankündigung Sanofi SA (Quelle DivvyDiary)
Ex-Tag: 30.05.2023

Zahltag: 01.06.2023

+ 6,91 %

Dividende 3,56 €

 

[Tordal]

Sanofi Non-GAAP EPS of €2.55, revenue of €11.96B; reaffirms FY23 outlook

 

Trotzdem -16 % derzeit, vielleicht deswegen: 

 

Pharmakonzern Sanofi plant Abspaltung der Sparte Consumer Healthcare 

Zitat

 

PARIS (dpa-AFX) - Der französische Pharmakonzern Sanofi plant eine Abspaltung seiner Sparte Consumer Healtcare. Das teilte das Unternehmen am Freitag in Paris im Rahmen der Vorlage der Zahlen zum dritten Quartal mit. Mit diesem Schritt will das Management seinen Fokus verstärkt auf die Biopharma-Sparte richten. Am wahrscheinlichsten sei die Gründung einer eigenen börsennotierten Gesellschaft, hieß es weiter. Die Abspaltung könnte bereits im vierten Quartal des nächsten Jahres vollzogen werden.

Den Ausblick für das laufende Jahr bestätigten die Pariser. Damit soll der bereinigte Gewinn je Aktie (EPS) währungsbereinigt weiterhin im mittleren einstelligen Prozentbereich wachsen. Im dritten Quartal lag der Gewinn je Aktie bei 2,55 Euro und damit unter den Erwartungen der Analysten. Der Umsatz stieg im gleichen Zeitraum währungsbereinigt um 3,2 Prozent auf 11,96 Milliarden Euro - ebenfalls weniger als Experten erwartet hatten

 

comdirect